AT1 FY21 - General Discussion + FA, page-1786

AT1 AGM completed; all Qs were answered (including mine paraphrased below):

During meeting:

- Covid19 self-test application has been submitted to TGA

- CEO also confirmed no issues in having Pantonic (Carestart) + Atomo brand Ag self-tests by TGA

Q) Previous geos like India, SouthEast Asia being targeted for Covid19 Ab tests and Ag test entry have not proceeded to health approval and product launch stages. Were these missteps in the FY21 plans/execution or dropped due to other factors?

A) Don’t believe these were missteps; Covid19 events have been fast moving; India market entry were based on pricing ability; these dynamics changed and there was no profit to be had in the end; so re-focused efforts elsewhere

Q) Previously the antibody rapid test (produced with NGBio) was announced as having a post-vaccine market for immunity and efficacy checks. What is happening in this space? Similarly are there any markets AT1 is planning to target with the antibody test produced with Access Bio company or has this also been dropped (since the supply agreement has been terminated)?

A) they are interested in this space (neutralising antibody tests mentioned in ppt); will disclose developments as available and allowed

Q) Could you please outline which gov and commercial sectors are being targeted for Covid19 antigen test orders and what has AT1’s success rate been so far in converting enquiries to supply orders?

A) channels aged care, industrials, corporates, logistics and transport, resources sector, looking to rollout int small biz with telehealth model with limited onsite resources; applying for available gov tenders with large volumes requirements (which they could not apply for prior to AccBio agreement)

Q) What is the status of the Pacific National company Covid19 test trials and if they were successful, do we expect this work to eventuate into a supply order?

A) won’t talk about individual companies; can say pilot was completed and successful; they continue to talk to a number of companies using this successful example

Q) Could you please outline the sales and marketing plan in Australia for Covid19 professional use (approved) vs consumer self-tests (pending approval)?

A) expanding commercial team; expanded into industrials, resources and partnering with various state gov tenders; recognise supply issues in country due to rapidly changed gov position; (repeated past info on all stock exhausted; significant supply coming in 3weeks); looking to submit VIC tender that is closing shortly; leveraging HIV biz channels/ecommerce channels and website etc

Q) What are the additional HIV test order sizes received from India/EU geos in comparison to the initial Viatris 250k order?

A) willnot disclose order sizes; Viatris order was disclosed as it was their firstorder for the UnitAid tender submitted w HIV market is materially growing;double in next 3-5years; if they get US approval they will be only 1 of 2approved brands

Other SH Qs:

- corporate social responsibility, addressing climate change and net zero goals

- timeline on Covid19 self-test

- why is the gov is not ordering from an Australian company rather than purchasing foreign brands for local use

- (there were a couple more minor Qs but couldn’t type fast enough